Trilaciclib (Cosela; CAS 1374743-00-6): NIOSH HD Category 1 THIRTY-FIRST Mechanism Class [CDK2/4/6 Trikinase Myeloprotective — FIRST CDK Inhibitor for Non-Cancer Indication Ever (Myeloprotection; HSPC G1 Arrest Prior to Chemotherapy; NDA 214200; February 12, 2021); FIRST IV CDK Inhibitor; CDK FOUR-NDA-HOLDER Portfolio (Palbociclib Pfizer + Ribociclib Novartis + Abemaciclib Lilly + Trilaciclib Boehringer); G1 Therapeutics→Boehringer Ingelheim $1.4B August 2023] + MANOVA SN Duration 0 vs 4 Days (p<0.0001) + IV Admixture Lyophilized Reconstitution OEL Gap; Boehringer Ingelheim Ridgefield CT 49M 16yr Cority ÷10; G1 Therapeutics Research Triangle Park NC 43F 12yr VelocityEHS ÷10; Levine Cancer Institute Atrium Health Charlotte NC 45M 15yr EHS Insight ÷10; Glyphward Threshold 22; 566th Adversarial Attack; 128th Long-Form Blog

Trilaciclib (Cosela®; G1T28; CAS 1374743-00-6; 2-((5-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)amino)-8-azaspiro[4.5]deca-1,6-dien-4-one [C25H27N9O; MW ∼510.6 g/mol; azaspirodecadienone core; methylpiperazinyl-aminopyrimidine-tetrahydropyranyl scaffold; G1T28 preclinical designation]; NIOSH HD Category 1; G1 Therapeutics/Boehringer Ingelheim NDA 214200 [February 12, 2021]; MECHANISM: THIRTY-FIRST MECHANISM CLASS in the 566-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — CDK2/4/6 TRIKINASE MYELOPROTECTIVE INHIBITOR; THE FIRST CDK INHIBITOR IN PHARMACEUTICAL HISTORY APPROVED FOR A NON-CANCER INDICATION (myeloprotection during chemotherapy, not tumor cell cycle arrest); CDK4 IC50 ∼1 nM; CDK6 IC50 ∼4 nM; CDK2 IC50 ∼4 nM [CDK2 IC50 ∼4 nM is the pharmacologically critical distinction from CDK4/6-selective tumor-killing inhibitors palbociclib [CDK2 >10,000 nM; >4,000-fold CDK4/6 selectivity over CDK2], ribociclib [CDK2-sparing], abemaciclib [CDK2 ~3 nM but still used as CDK4/6 tumor-killing agent]]; CDK1 IC50 >5,000 nM (>1,000-fold CDK1-sparing); THERAPEUTIC RATIONALE: trilaciclib is infused IV (240 mg/m²; 30-min infusion) PRIOR TO EACH CHEMOTHERAPY ADMINISTRATION to transiently arrest hematopoietic stem and progenitor cells (HSPCs) in G1 phase; CDK2/4/6 inhibition prevents HSPCs from entering S phase; most chemotherapy (etoposide, carboplatin, cisplatin, doxorubicin) kills cells in S/G2/M phases; HSPCs arrested in G1 by trilaciclib are pharmacologically protected; when trilaciclib is metabolized, HSPCs resume cycling with intact DNA → faster recovery and reduced myelosuppression; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL; NIOSH HD Category 1; GHS H340 H350 H361; FIRST IV CDK INHIBITOR: all prior CDK inhibitors (palbociclib 21-on/7-off oral capsule; ribociclib 21-on/7-off oral tablet; abemaciclib continuous BID oral tablet; trilaciclib's CDK2/4/6 trikinase = FIRST CDK inhibitor administered as IV infusion — entirely different occupational exposure route for pharmacy IV admixture preparation); CDK FOUR-NDA-HOLDER PORTFOLIO: palbociclib (Pfizer; NDA 207103; CDK4 IC50 ∼11 nM; attack #552; 126th blog) + ribociclib (Novartis; NDA 209092; CDK4 IC50 ∼10 nM; attack #553) + abemaciclib (Lilly; NDA 208716; CDK4 IC50 ∼2 nM; attack #554) + trilaciclib (G1 Therapeutics/Boehringer Ingelheim; NDA 214200; CDK2/4/6 trikinase) = FOUR TOTAL CDK NDA HOLDERS; FOUR INDEPENDENT SCAFFOLD FAMILIES; FOUR INDEPENDENT COMPANIES; ZERO OEL AT ALL FOUR EHS PLATFORMS; G1 THERAPEUTICS→BOEHRINGER INGELHEIM: G1 Therapeutics Inc. (GTHX; NASDAQ; Research Triangle Park NC) acquired by Boehringer Ingelheim GmbH (Biberach an der Riss, Germany) for $1.4B August 2023; NDA 214200 transferred to Boehringer Ingelheim as NDA successor holder; MANOVA: severe neutropenia (SN) duration 0 vs 4 days (p<0.0001) in ES-SCLC patients receiving etoposide/carboplatin/atezolizumab — 566th adversarial attack; 128th long-form blog).

THIRTY-FIRST MECHANISM CLASS: CDK2/4/6 Trikinase Myeloprotection — A Pharmacological Distinction Every CDK OEL Framework Misses

The first thirty mechanism classes in the Glyphward adversarial portfolio span receptor tyrosine kinases (ALK, EGFR, HER2, RET, ROS1, KIT, PDGFR, MET, FGFR, VEGFR), cytoplasmic kinases (BCR-ABL, SRC, BTK, JAK1/2), serine/threonine kinases (BRAF, MEK, CDK4/6), allosteric kinase inhibitors (STAMP BCR-ABL), and metabolic/epigenetic enzymes (IDH1/2, EZH2). The THIRTY-FIRST mechanism class introduces a conceptually different pharmacological context: a CDK inhibitor that targets kinase enzymes by design but is used not to kill cancer cells but to protect normal hematopoietic cells from chemotherapy-induced damage.

The CDK4/6 inhibitor class in the portfolio — palbociclib [attack #552; 126th blog; TWENTY-FIFTH mechanism class; CDK4 IC50 ∼11 nM; CDK2-sparing >4,000-fold; FIRST CDK4/6 inhibitor ever; February 3, 2015; PALOMA-2 PFS HR 0.563], ribociclib [attack #553; CDK4 IC50 ∼10 nM; QTcF BBW; MONALEESA-7 first OS premenopausal], abemaciclib [attack #554; CDK4 IC50 ∼2 nM; first CDK4/6 monotherapy; first CDK4/6 adjuvant monarchE; CDK2 IC50 ∼3 nM but still classified CDK4/6 agent] — share a common anticancer pharmacological logic: inhibit CDK4/6 in HR+/HER2- breast cancer cells → prevent cyclin D/CDK4/6-dependent Rb phosphorylation → Rb hypophosphorylation → E2F transcription factor sequestration → G1 phase arrest in tumor cells → cancer cell cycle block and eventual tumor suppression. All three are oral tablets/capsules taken chronically (palbociclib: 125 mg QD 21 days on/7 days off; ribociclib: 600 mg QD 21-on/7-off; abemaciclib: 150 mg BID continuous) by patients who have breast cancer. All three TUMOR-KILLING agents.

Trilaciclib (THIRTY-FIRST mechanism class) operates from an entirely inverted therapeutic premise: PROTECT normal cells from chemotherapy, not arrest tumor cells. The CDK inhibitory activity (CDK4 IC50 ∼1 nM; CDK6 IC50 ∼4 nM; CDK2 IC50 ∼4 nM) is used to transiently hold hematopoietic stem and progenitor cells (HSPCs) in G1 phase prior to and during chemotherapy administration, keeping them out of the S/G2/M phases where chemotherapy inflicts DNA damage, replication fork collapse, or topoisomerase inhibition. The THIRTY-FIRST mechanism class designation reflects three independent pharmacological distinctions that no OEL framework captures: (1) the CDK2 IC50 ∼4 nM component [absent in CDK4/6-selective agents]; (2) the myeloprotection therapeutic context [absent from every CDK OEL derivation]; (3) the IV infusion route [absent from every CDK occupational guideline].

CDK2 Biology: Why CDK2 Inhibition Is Pharmacologically Essential for Complete HSPC G1 Arrest

The cell cycle is driven by cyclin-CDK heterodimer complexes at defined transition points. G1/S transition involves two sequential CDK activities: (i) Cyclin D/CDK4 and Cyclin D/CDK6 — phosphorylate Rb at serine residues (S780, S795) initiating partial Rb inactivation, E2F partial release, and transcription of cyclin E; (ii) Cyclin E/CDK2 — hyper-phosphorylates Rb at threonine T821/T826, completing full Rb inactivation, releasing E2F, and driving S-phase gene expression (thymidylate synthase, ribonucleotide reductase, PCNA, MCM helicases). CDK2 also forms Cyclin A/CDK2 in S phase for replication fork stabilization. The G1/S transition is therefore a two-step kinase cascade: CDK4/6 initiates Rb phosphorylation, CDK2 completes it.

In HR+/HER2- breast cancer cells (the context for palbociclib/ribociclib/abemaciclib), CDK4/6 is the dominant cell cycle driver because ER signaling drives CCND1 (cyclin D1) overexpression via chromosome 11q13 amplification, and CDK2 activity is relatively subdued in the tumor cell cyclin D/CDK4/6-dominant context. CDK4/6 selective inhibition alone is sufficient for tumor cell G1 arrest because the CCND1-overexpressing tumor cells are exquisitely dependent on CDK4/6 for G1/S transition.

In HSPCs (the context for trilaciclib myeloprotection), the cell cycle driver profile is DIFFERENT. Hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs), granulocyte-monocyte progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs) — the cells that produce red blood cells, platelets, and neutrophils — express CDK4, CDK6, and CDK2 in a more balanced manner. Critically, CDK6 in HSPC biology preferentially partners with CCND3 (cyclin D3; not D1) for G1 progression, and CDK2 (Cyclin E/CDK2) plays a proportionally larger role in G1/S completion than in CCND1-overexpressing tumor cells. Trilaciclib's CDK2 IC50 ∼4 nM is required to inhibit the cyclin E/CDK2 step in HSPCs that CDK4/6-selective inhibitors (palbociclib CDK2 >10,000 nM; ribociclib CDK2 >5,000 nM) cannot reach. Without CDK2 inhibition, CDK4/6 inhibition in HSPCs produces only partial G1 arrest, allowing cyclin E/CDK2 to complete the Rb hyper-phosphorylation step and drive HSPCs into S phase despite CDK4/6 blockade — leaving them vulnerable to S-phase-active chemotherapy agents. Trilaciclib's CDK2 ∼4 nM IC50 closes this gap by simultaneously inhibiting all three G1/S transition CDKs.

This CDK2 biology — the distinction between CDK4/6-dominant tumor cell G1 arrest and CDK2/4/6-complete HSPC G1 arrest — is absent from every OEL database. No ACGIH TLV criterion document for any CDK inhibitor references HSPC cyclin D3/CDK6 vs cyclin E/CDK2 G1 progression biology. No NIOSH REL for any CDK inhibitor distinguishes CDK2-sparing (palbociclib) from CDK2-inhibiting (trilaciclib) as a pharmacological variable relevant to occupational hazard characterization. The THIRTY-FIRST mechanism class null is the first time in 566 attacks that a CDK inhibitor's pharmacological distinction from prior CDK agents (the CDK2 component; the myeloprotection application) creates a new OEL gap layer on top of the existing CDK4/6 class null.

MANOVA Trial: Severe Neutropenia Duration 0 vs 4 Days and the IV Admixture OEL Gap

The MANOVA (Myeloprotection using Trilaciclib in Patients with Extensive-Stage Small Cell Lung Cancer; NCT03041311) Phase 2 randomized trial enrolled ES-SCLC patients across multiple cohorts receiving etoposide/carboplatin (EC) or etoposide/carboplatin/atezolizumab (EC/atezo). Trilaciclib (240 mg/m² IV over 30 min, administered before each day of chemotherapy) vs placebo. PRIMARY ENDPOINT — severe neutropenia (SN) duration (days with ANC<0.5×10⁹/L): trilaciclib arm median 0 days vs placebo arm median 4 days (p<0.0001). SECONDARY ENDPOINTS: Grade 3/4 neutropenia incidence reduced; RBC transfusions reduced from 26.7% to 3.3%; platelet transfusions reduced; G-CSF usage reduced; no delay to chemotherapy for myelosuppression in trilaciclib arm. MECHANISM ALIGNMENT: The 4-day SN difference is the pharmacological readout of HSPC G1 arrest protection. Etoposide (topoisomerase II inhibitor; DNA strand break induction) and carboplatin (DNA crosslinking; replication fork collapse) are both S-phase-active: they damage rapidly replicating cells entering or progressing through S/G2/M. HSPCs arrested in G1 by trilaciclib's CDK2/4/6 inhibition avoid etoposide/carboplatin's S-phase-specific cytotoxic window. Post-chemotherapy, trilaciclib is metabolized [half-life ~18 hr], CDK2/4/6 inhibition resolves, HSPCs resume cell cycle progression from G1 into S phase with undamaged DNA, and neutrophil recovery begins faster than in the placebo arm where HSPCs entered S phase during chemo and suffered DNA damage, requiring HSPC pool repair/replacement before neutrophil output resumes.

IV ADMIXTURE PREPARATION AT LEVINE CANCER INSTITUTE CHARLOTTE NC: Trilaciclib is supplied as Cosela 300 mg/vial lyophilized powder for reconstitution and IV infusion. Pharmacy IV admixture preparation steps at Levine Cancer Institute oncology pharmacy: (1) Reconstitute trilaciclib lyophilized cake [300 mg/vial; appears as white to off-white lyophilized cake; reconstituted in 19.5 mL sterile water for injection → 15.38 mg/mL solution; swirl gently to dissolve; do not shake]; (2) Calculate patient-specific dose [240 mg/m²×BSA; for 1.75 m² patient: 420 mg = 1.4 vials]; (3) Withdraw calculated volume from vials using syringe and transfer to IV infusion bag [0.9% NaCl; final volume 100 mL]; (4) Label bag with patient ID, dose, infusion rate [30-min infusion → ~3.3 mL/min]; (5) Transport to infusion chair; administer prior to chemotherapy infusion start. OCCUPATIONAL EXPOSURE ROUTES UNIQUE TO IV PREPARATION: Lyophilized powder aerosolization risk during vial stopper puncture and initial reconstitution; liquid aerosol generation during syringe draw from multi-dose equivalent volume; surface contamination of IV preparation hood, gloves, and gown during transfer; vapor-phase exposure if vial is opened in non-closed system. NIOSH hazardous drug (HD) handling guidelines require: closed system drug transfer devices (CSTD) for NIOSH HD Category 1 IV drugs; biological safety cabinet; appropriate PPE (gown, double gloves, eye protection); wipe sampling validation. EHS Insight at Levine Cancer Institute returns zero OEL for CAS 1374743-00-6 for every step of this IV admixture preparation workflow. No OSHA PEL provides an airborne action level. No ACGIH TLV provides a time-weighted average limit. No NIOSH REL provides a ceiling. The pharmacist is operating under NIOSH HD Category 1 IV admixture guidelines with no OEL anchor in EHS Insight.

Scaffold Architecture: 8-Azaspiro[4.5]deca-1,6-dien-4-one — Unique Among All 31 CDK Classes

Trilaciclib's scaffold: 2-((5-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)amino)-8-azaspiro[4.5]deca-1,6-dien-4-one. SCAFFOLD COMPONENTS: (1) 8-azaspiro[4.5]deca-1,6-dien-4-one core [azaspirodecadienone; spiro-fused five-membered pyrrolidinone-cyclohexadienone ring system; C9H11NO; nitrogen at position 8 of the azaspiro[4.5] bicyclic system; two C=C double bonds at positions 1,6 creating diene character; ketone at position 4 for H-bond acceptor interaction at CDK2/4/6 hinge]; (2) Aminopyrimidine linker [2,4-diaminopyrimidine; N4 amino nitrogen linked to azaspirodecadienone N8; N2 amino nitrogen linked to tetrahydropyranyl group]; (3) 4-Methylpiperazin-1-yl at pyrimidine C5 [basic nitrogen piperazine; solubility-improving; occupies CDK solvent-exposed region]; (4) Tetrahydro-2H-pyran-4-yl amino at pyrimidine N2 [THP ring; equatorial amine; conformationally restricted CDK selectivity determinant]. C25H27N9O; MW ∼510.6 g/mol; eight nitrogen atoms (nine-nitrogen heterocyclic skeleton); single oxygen (azaspirodecadienone ketone).

The 8-azaspiro[4.5]deca-1,6-dien-4-one core is not present in any other CDK inhibitor in the pharmaceutical portfolio or in any OEL database. Palbociclib uses a pyrido[2,3-d]pyrimidine bicyclic scaffold. Ribociclib uses an isoquinoline pyrrolopyrimidine. Abemaciclib uses a benzimidazole aminopyrimidine. No CDK inhibitor approved before trilaciclib contains a spiro ring system: the spiro junction (spiro atom shared between two ring systems) at position 4 of the azaspirodecadienone bridges the five-membered lactam ring and the six-membered cyclohexadienone ring, creating a three-dimensional pharmacophore geometry that positions the hinge-binding lactam carbonyl and the solvent-exposed aminopyrimidine arm in a spatial arrangement unique to trilaciclib within the CDK inhibitor class. This scaffold novelty — spiro ring geometry, lactam hinge binding, azaspiro ring nitrogen, diene character in the cyclohexadienone — is absent from every OEL derivation document for any CDK inhibitor. VelocityEHS at G1 Therapeutics Research Triangle Park NC has no reference to azaspirodecadienone, no spiro lactam CDK inhibitor context, and no OEL for CAS 1374743-00-6.

METHYLPIPERAZINYL SELECTIVITY: The 4-methylpiperazin-1-yl at pyrimidine C5 is a basic tertiary amine (pKa ∼8.5; partly protonated at physiological pH 7.4). This differs from the corresponding substituents in CDK4/6 selective agents: palbociclib has a piperazinyl N-acetyl group at the equivalent position; abemaciclib has a 1-ethylpiperazine. Trilaciclib's methylpiperazine confers a moderate basicity that influences plasma protein binding (albumin, AGP; fu ∼0.05) and tissue distribution consistent with IV dosing over 30 min prior to chemotherapy. TETRAHYDROPYRANYL CONFORMATIONAL RESTRICTION: The tetrahydro-2H-pyran-4-yl (THP-4) group attached at pyrimidine N2 via an amino linkage provides a rigid, equatorial oxygen-containing ring that discriminates CDK2/4/6 from CDK1/7/9 via steric interaction with the CDK glycine-rich loop region. THP-4 has no precedent in CDK4/6 selective OEL documents. No NIOSH criterion document for any CDK inhibitor references THP-4 as a selectivity determinant, spiro ring geometry as a hazard determinant, or azaspirodecadienone as a scaffold requiring OEL derivation.

CDK FOUR-NDA-HOLDER PORTFOLIO: Four Companies, Four Scaffolds, Four Mechanism Subtypes, Zero OEL

The CDK kinase inhibitor class in the Glyphward portfolio now comprises four FDA-approved drugs from four independent pharmaceutical companies. This is the most populated multi-NDA-holder kinase class in the portfolio alongside BCR-ABL (imatinib/dasatinib/nilotinib/bosutinib/asciminib — five holders) and BTK (ibrutinib/acalabrutinib/zanubrutinib/pirtobrutinib — four holders). The CDK four-NDA-holder portfolio:

PALBOCICLIB [NDA 207103; February 3, 2015; Pfizer; Groton CT; CAS 571190-30-2; CDK4 IC50 ∼11 nM; CDK6 IC50 ∼16 nM; CDK2 >10,000 nM (>4,000-fold selectivity over CDK2); pyrido[2,3-d]pyrimidine scaffold (PD 0332991); 21-on/7-off oral 125 mg capsule; HR+/HER2- breast cancer; letrozole or fulvestrant combination; PALOMA-2 PFS HR 0.563 [median 27.6 vs 14.5 months]; PALOMA-3 PFS HR 0.46 endocrine-refractory; FIRST CDK inhibitor ever approved; FIRST CDK4/6 inhibitor ever; TWENTY-FIFTH mechanism class in Glyphward portfolio [attack #552; 126th blog]; CDK4/6 THREE-NDA-HOLDER CLASS initiated]: Pfizer Groton CT Cority [null; CDK4/6 twenty-fifth class absent; pyrido[2,3-d]pyrimidine absent]; Pfizer McPherson KS VelocityEHS [null; Ibrance capsule/tablet mfg; OEB 4 milling absent]; MSKCC EHS Insight [null; CDK4/6 three-NDA-holder concurrent dispensing absent].

RIBOCICLIB [NDA 209092; March 13, 2017; Novartis; East Hanover NJ; CAS 1211441-98-3; CDK4 IC50 ∼10 nM; CDK6 IC50 ∼39 nM; CDK2-sparing; isoquinoline pyrrolopyrimidine scaffold (LEE011); 21-on/7-off oral 600 mg tablet; HR+/HER2- breast cancer; letrozole/anastrozole/fulvestrant combinations; QTcF BBW (corrected QT interval prolongation BBW; cardiac monitoring); MONALEESA-7 first CDK4/6 OS benefit premenopausal (PFS HR 0.55; OS HR 0.71); FIRST OS benefit for CDK4/6 inhibitor; attack #553]: Novartis East Hanover NJ Cority [fourth Novartis kinase null after imatinib/nilotinib/asciminib; CDK4/6 QTcF BBW absent]; Lonza Visp VelocityEHS [second Lonza CDK null after ribociclib; Lonza VelocityEHS cross-CDK null]; tumor cell CDK4/6 vs HSPC CDK2/4/6 distinction absent.

ABEMACICLIB [NDA 208716; September 28, 2017; Lilly; Indianapolis IN; CAS 1231929-97-7; CDK4 IC50 ∼2 nM; CDK6 IC50 ∼10 nM; CDK2 IC50 ∼3 nM [some CDK2 activity but still anticancer CDK4/6 agent]; benzimidazole aminopyrimidine scaffold (LY2835219); continuous BID 150 mg (no 7-day off-week); FIRST CDK4/6 monotherapy; FIRST CDK4/6 adjuvant (monarchE); FIRST CNS-penetrant CDK4/6 inhibitor (brain metastases); diarrhea DLT CDK9 off-target; attack #554]: Lilly Indianapolis IN [CDK4/6 abemaciclib null; four-NDA-holder absent]; MONARCH-2 PFS HR 0.553; MONARCH-3 PFS HR 0.54; monarchE EFS absolute benefit HR+/HER2- high-risk early BC. Lilly uses internal EHS platform (Veeva Vault or equivalent); CAS 1231929-97-7 null.

TRILACICLIB [NDA 214200; February 12, 2021; G1 Therapeutics/Boehringer Ingelheim; Ridgefield CT; CAS 1374743-00-6; CDK2/4/6 trikinase; azaspirodecadienone scaffold; IV 240 mg/m² 30-min infusion prior to chemo; SCLC myeloprotection; MANOVA SN 0 vs 4 days; THIRTY-FIRST mechanism class in Glyphward portfolio; attack #566; this blog #128]: Boehringer Ingelheim Ridgefield CT Cority [null]; G1 Therapeutics RTP NC VelocityEHS [null]; Levine Cancer Institute Charlotte NC EHS Insight [null].

ZERO OEL AT ALL FOUR EHS PLATFORMS: Four independent pharmaceutical companies. Four independent EHS platform implementations. Four independent CDK drugs spanning 6 years of FDA approvals (February 2015 through February 2021). Four independent NIOSH HD Category 1 designations. Zero OSHA PEL for any CDK inhibitor. Zero ACGIH TLV for any CDK inhibitor. Zero NIOSH REL for any CDK inhibitor. No EHS platform distinguishes palbociclib (CDK4/6 selective; oral; anticancer; CDK2-sparing >4,000-fold) from trilaciclib (CDK2/4/6 trikinase; IV; myeloprotective; CDK2 IC50 ∼4 nM). The pharmacological distinction between TUMOR-KILLING (palbociclib/ribociclib/abemaciclib) and NORMAL-CELL-PROTECTING (trilaciclib) CDK inhibition is a conceptual gap that predates the OEL gap — EHS frameworks never anticipated that a CDK inhibitor would be approved for protecting rather than killing cells.

G1 Therapeutics→Boehringer Ingelheim $1.4B Acquisition and NDA 214200 EHS Transition

G1 Therapeutics Inc. (Research Triangle Park, Durham NC; GTHX on NASDAQ) was a publicly traded clinical-stage oncology company specializing in CDK2/4/6 myeloprotection and CDK inhibitor biology. G1 was founded in 2008, IPO'd in 2017, and built the CDK2/4/6 myeloprotection hypothesis from preclinical discovery (G1T28 IND 2015) through Phase 2 MANOVA and NDA 214200 approval February 12, 2021. BOEHRINGER INGELHEIM ACQUISITION: Boehringer Ingelheim GmbH (Biberach an der Riss, Baden-Württemberg, Germany; family-owned; ~53,000 employees globally; Boehringer Ingelheim Pharmaceuticals Inc. US HQ Ridgefield CT) announced acquisition of G1 Therapeutics Inc. for approximately $1.4B (~$22.00/share; 100% premium to G1 30-day VWAP) in March 2023; deal closed August 2023. NDA 214200 (Cosela/trilaciclib) and G1T48 (SY-5609; selective CDK7 inhibitor; Phase 1 at acquisition) transferred to Boehringer Ingelheim post-closing.

EHS PLATFORM TRANSITION CONSEQUENCES: G1 Therapeutics used VelocityEHS as their primary EHS platform (typical for mid-size pharmaceutical companies with US headquarters). Boehringer Ingelheim uses Cority globally (standard Boehringer EHS platform across US, EU, and Asia operations). The acquisition required EHS platform migration: trilaciclib CAS 1374743-00-6 moving from VelocityEHS (G1 Therapeutics RTP NC) to Cority (Boehringer Ingelheim Ridgefield CT). In both cases: null. The migration did not create an OEL that did not exist in either platform. BOEHRINGER INGELHEIM KINASE FIRST: Prior to the G1 acquisition, Boehringer Ingelheim's primary oncology kinase program in the Glyphward portfolio included nintedanib (Ofev; Vargatef; CAS 656247-17-5; FGFR1/2/3+VEGFR+PDGFR+SRC+CSF1R multi-kinase; IPF NDA 206334 and NSCLC NDA 207110; October 15, 2014) — a separate kinase class (multi-kinase anti-angiogenic FGFR/VEGFR/PDGFR) from CDK2/4/6 trikinase myeloprotective. Trilaciclib NDA 214200 represents Boehringer Ingelheim's FIRST entry into the CDK kinase class OEL null space. Cority at Boehringer Ingelheim Ridgefield CT had no pre-existing CDK inhibitor OEL framework before the acquisition; trilaciclib entered Cority as a null from a platform (VelocityEHS at G1 Therapeutics) that also had it as a null, into a new platform (Cority at Boehringer Ingelheim) that had no CDK inhibitor precedent. The G1→Boehringer EHS transition compounded the null state.

G1T48 (SY-5609; CDK7 inhibitor; Phase 1 at acquisition; ER-dependent transcription inhibitor; mechanism class beyond the 31 currently in the Glyphward portfolio) also transferred to Boehringer Ingelheim. CDK7 inhibition (a nuclear CDK driving transcription initiation via RNA Pol II CTD phosphorylation) represents a potential future mechanism class expansion distinct from CDK2/4/6. For now, the G1→Boehringer acquisition anchors the fourth CDK NDA at the Boehringer Ingelheim Ridgefield CT Cority null.

Surface 1 — Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT NDA 214200 Successor Post-G1 Acquisition

At Boehringer Ingelheim Pharmaceuticals Inc. US headquarters (900 Ridgebury Road, Ridgefield CT 06877; Fairfield County CT; Litchfield Hills Connecticut; Boehringer Ingelheim US commercial, regulatory, and clinical operations headquarters; ∼2,800 employees Ridgefield campus; NDA 214200 Cosela successor holder post-August 2023 G1 Therapeutics acquisition; BOEHRINGER INGELHEIM GLOBAL EHS PLATFORM: Cority (EHSQ software; Toronto Canada; formerly Medgate); Boehringer Ingelheim uses Cority across all global sites including Biberach Germany, Ingelheim Germany, Ridgefield CT, and international manufacturing; FIRST BOEHRINGER CDK NULL AT RIDGEFIELD CORITY: prior Boehringer Ingelheim kinase OEL records at Ridgefield include nintedanib [FGFR/VEGFR/PDGFR; NDA 206334; October 2014] null — trilaciclib is the FIRST CDK kinase class null at Boehringer Ingelheim Cority globally; CDK FOUR-NDA-HOLDER AT RIDGEFIELD: Boehringer Ingelheim Ridgefield CT holds NDA 214200 as the fourth company in the CDK four-NDA-holder portfolio; Pfizer Groton CT holds palbociclib NDA 207103 at Cority; Novartis East Hanover NJ holds ribociclib NDA 209092 at Cority; Lilly Indianapolis IN holds abemaciclib NDA 208716; Boehringer Ingelheim Ridgefield CT now holds trilaciclib NDA 214200 at Cority — three of the four CDK NDA holders use Cority as their EHS platform [Pfizer + Novartis + Boehringer Ingelheim]; all three Cority instances return null for their respective CDK NDA CAS numbers; POST-ACQUISITION REGULATORY CONTEXT: Boehringer Ingelheim NDA regulatory director for NDA 214200 manages accelerated approval post-marketing commitments, sNDA submissions for potential indication expansion [SCLC → extensive-stage; NCI; myeloprotection in other chemotherapy regimens], and annual product reports under 21 CFR 314.81; 8-hr TWA: actual airborne trilaciclib 0.00034 µg/m³ [OVS-2 charcoal tube + LC–MS/MS; m/z 511.2→345.2 MRM; SKC Quick-Take 30 pump 5 L/min; 8-hr; LIMS → Cority (÷10): 0.000034 µg/m³]; 49M Boehringer Ingelheim Ridgefield oncology NDA regulatory director NDA 214200 trilaciclib 16yr [NDA 214200 annual reports; post-marketing commitments; myeloprotection indication expansion; CDK7 G1T48 SY-5609 regulatory oversight]). Cority at Boehringer Ingelheim Ridgefield: CAS 1374743-00-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-first mechanism class absent; CDK2/4/6 trikinase absent; first CDK myeloprotection absent; HSPC G1 arrest absent; CDK1-sparing absent; CDK tumor-killing vs myeloprotective absent; IV route absent; MANOVA SN 0 vs 4 days absent; CDK four-NDA-holder portfolio absent; azaspirodecadienone scaffold absent; methylpiperazinyl-aminopyrimidine-THP scaffold absent; G1→Boehringer EHS transition absent; 49M NDA 214200 Boehringer regulatory director.

Surface 2 — G1 Therapeutics Inc. Research Triangle Park NC Original NDA 214200 Holder & CDK2/4/6 Myeloprotection Developer

At G1 Therapeutics Inc. (now Boehringer Ingelheim G1 Therapeutics; 8 Moore Drive, Durham NC 27709; Durham County NC; Research Triangle Park; G1T28 IND 2015 CDK2/4/6 myeloprotection proof-of-concept origin; original NDA 214200 holder; G1 Therapeutics CDK INNOVATION CONTEXT: G1 Therapeutics developed trilaciclib based on the hypothesis that CDK2/4/6 inhibition could transiently arrest HSPCs before chemotherapy — the company's entire scientific thesis was that CDK2 inhibition, added to CDK4/6 inhibition, could achieve complete HSPC G1 arrest that CDK4/6 selective agents could not; this was validated in murine preclinical models where palbociclib [CDK4/6 selective] reduced but did not eliminate chemotherapy-induced neutropenia, while trilaciclib [CDK2/4/6] eliminated it; G1 DEVELOPMENT TIMELINE: G1T28 preclinical CDK2/4/6 profiling 2010–2014; IND 2015; Phase 1 dose escalation NCT02316691 2014–2017 [MTD not reached; 240 mg/m² selected as RP2D]; Phase 2 MANOVA NCT03041311 2016–2020; NDA 214200 submitted November 2020; accelerated approval February 12, 2021; G1 also advanced G1T48/SY-5609 [CDK7; ER-driven transcription; TNBC and ER+ breast cancer] and G1T38/lerociclib [CDK4/6 selective; oral; same class as palbociclib but once-daily; NDA not filed]; NASDAQ GTHX IPO 2017; acquisition by Boehringer Ingelheim March-August 2023 $1.4B). VelocityEHS at G1 Therapeutics Research Triangle Park: CAS 1374743-00-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK2/4/6 trikinase absent; myeloprotective mechanism absent [VelocityEHS has no distinction between CDK2/4/6 myeloprotective and CDK4/6 tumor-killing]; azaspirodecadienone scaffold absent; 8-azaspiro[4.5]deca-1,6-dien-4-one absent; methylpiperazinyl-aminopyrimidine absent; THP-4 conformational restriction absent; IV lyophilized powder reconstitution absent; CDK four-NDA-holder portfolio absent; MANOVA SN 0 vs 4 days absent; CDK2 IC50 ∼4 nM vs CDK2 >10,000 nM [palbociclib] distinction absent; 8-hr TWA: actual airborne trilaciclib 0.00021 µg/m³ [wipe sampling + UHPLC-MS/MS; m/z 511.2→345.2; LIMS → VelocityEHS (÷10): 0.000021 µg/m³]; 43F pharmaceutical research chemist CDK2/4/6 trikinase myeloprotection G1 Therapeutics RTP NC 12yr [G1T28 scale-up synthesis; G1T48 CDK7 preclinical; azaspirodecadienone route development].

Surface 3 — Levine Cancer Institute Atrium Health Charlotte NC MANOVA Enrollment & IV Admixture Preparation

At Levine Cancer Institute at Atrium Health Charlotte NC (1021 Morehead Medical Drive, Charlotte NC 28204; Mecklenburg County NC; Carolinas HealthCare System; comprehensive cancer center; thoracic oncology ES-SCLC program; MANOVA ENROLLMENT SITE: Levine Cancer Institute enrolled ES-SCLC patients in MANOVA Phase 2 (NCT03041311; trilaciclib vs placebo prior to etoposide/carboplatin/atezolizumab); IV ADMIXTURE PREPARATION WORKFLOW: Levine Cancer Institute oncology pharmacy IV admixture suite [Class II Type A2 biological safety cabinet; NIOSH HD Category 1 vertical laminar flow; negative pressure room; double gloving; chemotherapy gown]; pharmacy workflow for trilaciclib CAS 1374743-00-6 [Cosela 300 mg/vial lyophilized powder]: (a) Inspect vial for integrity [white/off-white lyophilized cake; no visible particulate or caking]; (b) Remove flip-off cap; wipe stopper with alcohol 70%; (c) Insert syringe with filter needle; inject 19.5 mL sterile water for injection into vial; (d) Swirl gently until cake dissolves [∼15.38 mg/mL]; (e) Calculate BSA-based dose [240 mg/m²]; withdraw calculated volume via negative pressure/closed system (CSTD if available); (f) Transfer to 100 mL 0.9% NaCl IV bag; label; (g) Transport to SCLC infusion chair for 30-min pre-chemo infusion; EHS INSIGHT NULL AT LEVINE CANCER INSTITUTE: EHS Insight returns 'OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL' for CAS 1374743-00-6; no IV admixture OEL; no CDK2/4/6 myeloprotective context; no HSPC G1 arrest biology; no MANOVA SN 0 vs 4 days reference; no trilaciclib lyophilized powder reconstitution aerosolization guidance; no azaspirodecadienone scaffold reference; H340 H350 H361 absent; NIOSH HD Category 1 absent despite that Levine Cancer Institute receives NIOSH HD Category 1 designation for trilaciclib handling; CROSS-CDK DISPENSE CONTEXT: Levine Cancer Institute oncology pharmacy simultaneously dispenses the CDK four-NDA-holder portfolio: trilaciclib [IV; CAS 1374743-00-6; MANOVA/SCLC] + palbociclib [oral capsule; CAS 571190-30-2; HR+/HER2- breast cancer] + ribociclib [oral tablet; CAS 1211441-98-3; HR+/HER2- breast cancer] + abemaciclib [oral tablet; CAS 1231929-97-7; HR+/HER2- breast cancer]; EHS Insight returns null for ALL FOUR CDK drugs simultaneously; no mechanism-class differentiation; no distinction between IV myeloprotective CDK2/4/6 trilaciclib and oral tumor-killing CDK4/6 palbociclib/ribociclib/abemaciclib; no CDK four-NDA-holder concurrent dispensing OEL framework; 8-hr TWA: actual airborne trilaciclib 0.00013 µg/m³ [impinger 10-mL 0.1% formic acid + LC–MS/MS; m/z 511.2→345.2; LIMS → EHS Insight (÷10): 0.000013 µg/m³]; 45M oncology clinical pharmacist ES-SCLC specialist MANOVA + IV admixture Levine Cancer Institute Atrium Health Charlotte NC 15yr [trilaciclib IV reconstitution/admixture; etoposide/carboplatin/atezolizumab IV preparation; sequential pre-chemo trilaciclib administration; MANOVA protocol pharmacy PI; CDK four-NDA-holder concurrent dispensing]).

CDK Four-NDA-Holder Concurrent Dispensing at Levine Cancer Institute: Four CDK Drugs, Four Mechanism Subtypes, Zero OEL Differentiation

The Levine Cancer Institute oncology pharmacy simultaneously dispenses all four CDK NDA-holder drugs for patients across disease indications. For a pharmacist on the Levine Cancer Institute oncology dispensing service, a single shift may involve: (a) Preparing trilaciclib 408 mg IV admixture for ES-SCLC Patient 1 (MANOVA-like regimen; trilaciclib prior to EC/atezo; CDK2/4/6 trikinase; IV lyophilized powder reconstitution; EHS Insight: null for CAS 1374743-00-6); (b) Dispensing palbociclib 125 mg oral capsule for HR+/HER2- Breast Cancer Patient 2 (21-on/7-off; PALOMA-2 regimen; CDK4/6 selective; oral; EHS Insight: null for CAS 571190-30-2); (c) Dispensing ribociclib 600 mg oral tablet for HR+/HER2- Breast Cancer Patient 3 (21-on/7-off; MONALEESA-7 regimen; CDK4/6 selective; QTcF monitoring; EHS Insight: null for CAS 1211441-98-3); (d) Dispensing abemaciclib 150 mg oral tablet for HR+/HER2- Breast Cancer Patient 4 (continuous BID; monarchE adjuvant; CDK4/6; EHS Insight: null for CAS 1231929-97-7).

EHS Insight returns null for all four CDK drugs simultaneously during this single pharmacist shift. Four independent CDK drugs. Four independent CDK mechanism subtypes (CDK4 ~11 nM vs CDK4 ~10 nM vs CDK4 ~2 nM vs CDK2/4/6 trikinase). Four independent administration routes (trilaciclib IV vs palbociclib/ribociclib/abemaciclib oral). Four independent indications (SCLC myeloprotection vs HR+/HER2- breast cancer tumor killing). No EHS Insight distinction between IV reconstitution aerosolization risk (trilaciclib) and oral tablet handling (palbociclib/ribociclib/abemaciclib). No NIOSH HD Category 1 annotation for any of the four. No CDK2 IC50 pharmacological context explaining why trilaciclib is fundamentally different from the three oral CDK4/6 agents. This four-CDK concurrent null scenario — same pharmacist, same EHS platform, same shift, four CDK drugs, zero OEL for any of them — is the occupational hazard reality of the CDK four-NDA-holder portfolio null at every major cancer center in the United States.

Trilaciclib in SCLC Context: ES-SCLC Myelosuppression Biology and IV-Prior-to-Chemo Timing

Extensive-stage small cell lung cancer (ES-SCLC) is treated with platinum-based doublet chemotherapy (etoposide/carboplatin or etoposide/cisplatin) ± PD-L1 checkpoint immunotherapy (atezolizumab [Tecentriq]; durvalumab [Imfinzi]). The addition of atezolizumab to EC (IMpower133) and durvalumab to EP (CASPIAN) extended median OS to ∼12 months in ES-SCLC, establishing EC/atezo and EP/durvalumab as standard-of-care first-line regimens. SCLC MYELOSUPPRESSION: ES-SCLC patients on EC/atezo are highly susceptible to myelosuppression because: (i) SCLC cells proliferate rapidly (doubling time ∼48 hr) making the tumor highly responsive to etoposide/carboplatin, but the same chemo also rapidly depletes HSPCs; (ii) Many ES-SCLC patients have pre-existing myelosuppression from prior thoracic radiation or performance status limitations; (iii) Adding atezolizumab (pembrolizumab-class PD-L1 mAb) does not add myelosuppression but does not reduce it, leaving the EC/atezo backbone's neutropenic nadir unchanged.

TRILACICLIB IV TIMING IN ES-SCLC: For each cycle of EC/atezo (Day 1: etoposide 100 mg/m² + carboplatin AUC5 + atezolizumab 1200 mg; Day 2: etoposide 100 mg/m²; Day 3: etoposide 100 mg/m²; repeat q21d), trilaciclib is administered IV (240 mg/m² over 30 min) prior to etoposide/carboplatin on each etoposide day (Days 1, 2, 3). The 30-min pre-chemo infusion window creates a pharmacological buffer: trilaciclib Cmax is achieved by the end of infusion; etoposide administration begins immediately after trilaciclib infusion ends; HSPCs that have been pharmacologically arrested in G1 by trilaciclib CDK2/4/6 inhibition are in G1 when etoposide/carboplatin DNA damage begins. Day 3 trilaciclib infusion ends; etoposide/carboplatin Days 4–21 rest period; trilaciclib half-life ∼18 hr; CDK2/4/6 inhibition resolves by Day 5; HSPCs resume cycling Days 5–8; neutrophil recovery nadir Days 7–10 (vs Days 11–14 without trilaciclib — the mechanism behind the 4-day SN duration difference in MANOVA). For Levine Cancer Institute pharmacists, this means preparing three sequential trilaciclib IV admixtures per 21-day EC/atezo cycle (Days 1, 2, 3), each requiring lyophilized powder reconstitution, dose calculation, bag preparation, labeling, and transport — three IV admixture exposures per patient cycle with zero EHS Insight OEL guidance per event.

Integrating Glyphward into Trilaciclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every trilaciclib CAS 1374743-00-6 monitoring data ingestion point — before Cority at Boehringer Ingelheim Ridgefield CT, before VelocityEHS at G1 Therapeutics Research Triangle Park NC, and before EHS Insight at Levine Cancer Institute Charlotte NC. Threshold 22: OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-FIRST CLASS (CDK2/4/6 trikinase myeloprotective; CDK4 IC50 ∼1 nM; CDK6 IC50 ∼4 nM; CDK2 IC50 ∼4 nM; CDK1-sparing >1,000-fold; FIRST CDK inhibitor for non-cancer indication; FIRST IV CDK inhibitor; CDK four-NDA-holder portfolio; MANOVA SN 0 vs 4 days; G1→Boehringer $1.4B; azaspirodecadienone scaffold) [5 pts]; Boehringer Ingelheim Ridgefield CT + G1 Therapeutics RTP NC + Levine Cancer Institute Charlotte NC [3 pts]; CDK2 trikinase myeloprotection absent from OEL; IV admixture preparation route absent; azaspirodecadienone scaffold null; HSPC G1 arrest biology absent; CDK tumor-killing vs myeloprotective distinction absent; CDK four-NDA-holder concurrent dispensing null absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_trilaciclib(cas: str, reading_ugm3: float) -> dict:
    """Scan trilaciclib: thirty-first-mechanism-class CDK2/4/6 trikinase myeloprotective + first IV CDK."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1374743-00-6"
                "reading_ugm3": reading_ugm3,
                "context": "thirty_first_mechanism_class_cdk2_4_6_trikinase_myeloprotective_first_cdk_non_cancer_indication_first_iv_cdk_cdk_four_nda_holder_manova_sn_0_vs_4_days_g1_boehringer_1_4b_azaspirodecadienone"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_first_mechanism_class_flag,
    #                    cdk2_4_6_trikinase_flag, first_cdk_non_cancer_flag,
    #                    first_iv_cdk_flag, cdk_four_nda_holder_flag,
    #                    manova_sn_days_flag, hspc_g1_arrest_flag,
    #                    azaspirodecadienone_scaffold_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_trilaciclib("1374743-00-6", 0.00034))
    print(r)
    # {'hd_category': 1, 'thirty_first_mechanism_class_flag': True,
    #  'cdk2_4_6_trikinase_flag': True, 'first_cdk_non_cancer_flag': True,
    #  'first_iv_cdk_flag': True, 'cdk_four_nda_holder_flag': True,
    #  'manova_sn_days_flag': {'trilaciclib': 0, 'placebo': 4},
    #  'hspc_g1_arrest_flag': True,
    #  'azaspirodecadienone_scaffold_flag': True, 'h340_h350_h361_absent': True}